FDA Approves Leucovorin for Rare Disorder, Not Autism

The Food and Drug Administration approved leucovorin this week for a rare genetic disorder that limits folate delivery to the brain, while explicitly walking back claims by President Donald Trump and other administration officials that the drug holds broad promise for children with autism.

The approval covers children and adults with cerebral folate deficiency, a genetic condition so uncommon that FDA officials estimate it affects fewer than one in a million people in the United States. Patients with the condition suffer movement disorders, seizures, and other neurological problems that can resemble autism symptoms. For that narrow population, Tuesday’s approval represents a genuine advance.

What it does not represent is a breakthrough for autism treatment, despite months of signals from the White House suggesting otherwise.

Last September, Trump and FDA Commissioner Marty Makary held a news conference at which they announced the drug was under review for autism. Makary claimed the folate deficiency that leucovorin targets might affect “20, 40, 50% of kids with autism.” The event came on the heels of Health Secretary Robert F. Kennedy Jr. pledging to identify the cause of autism by that same month.

None of those claims held up under scientific review.

Senior FDA officials told reporters Monday that the agency narrowed its evaluation to focus on the strongest available evidence. That evidence supported only the drug’s use in patients with the confirmed genetic mutation affecting folate transport to the brain. The officials also noted that one study cited in support of leucovorin’s use for autism was retracted earlier this year.

The American Academy of Pediatrics does not recommend routine leucovorin use for autistic children, including those who also have cerebral folate deficiency. Some small trials in that subset of patients “suggest potential benefit,” the group acknowledges, but the research base is too limited to support a broad clinical recommendation.

That has not stopped off-label prescribing. Physicians across the country have been writing prescriptions for leucovorin for autistic patients even without FDA sanction, a pattern that tends to accelerate when high-profile figures attach themselves to unproven treatments.

Leucovorin is not a new drug. It has long carried FDA approval for reducing side effects from certain chemotherapy regimens and for treating a rare blood disorder. It is a synthetic metabolite of folate, the B vitamin that supports healthy fetal development and is recommended for women before and during pregnancy. The new approval adds cerebral folate deficiency to its label. It does not open the door to autism treatment, at least not through this regulatory pathway.

The episode illustrates a pattern that has become familiar during the current administration’s approach to medical science. A promising but preliminary signal gets amplified well beyond what the data supports. Officials make public commitments tied to political timelines. Then scientists, when given the space to do their jobs, produce a narrower and more honest result.

For the families of children who actually have cerebral folate deficiency, Tuesday’s news is straightforwardly good. They now have a drug with formal FDA approval, clearer prescribing guidance, and a stronger regulatory foundation for accessing treatment and insurance coverage.

For the much larger number of families affected by autism, the message from federal scientists this week was clear. The evidence for leucovorin does not support its broad use. One study that advocates pointed to was retracted. The professional medical community has not endorsed it. And the sweeping claims made from a White House podium last year did not survive contact with a rigorous review process.

Dallas families navigating autism diagnoses deserve accurate information, not hope manufactured for a news cycle. The FDA’s decision this week, whatever its political awkwardness for the administration, reflects how drug approval is supposed to work. A real benefit was confirmed for a real condition. A claim that outran the evidence was corrected.

That is the system functioning as designed, even when the pressure to do otherwise came from the top.